Cargando…

An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial

BACKGROUND: This study was designed to evaluate the occurrence and severity of ocular hyperemia in subjects with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) following treatment with bimatoprost 0.01% in a real-world clinical setting. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nixon, Donald R, Simonyi, Susan, Bhogal, Meetu, Sigouin, Christopher S, Crichton, Andrew C, Discepola, Marino, Hutnik, Cindy ML, Yan, David B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529655/ https://www.ncbi.nlm.nih.gov/pubmed/23269858 http://dx.doi.org/10.2147/OPTH.S35394

Ejemplares similares

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial
por: Crichton, Andrew C, et al.
Publicado: (2014)

Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting
por: Park, Ki Ho, et al.
Publicado: (2014)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
por: Chen, Ying Ying, et al.
Publicado: (2016)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Pfennigsdorf, Stefan, et al.
Publicado: (2012)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure
por: Tung, Jonathan D, et al.
Publicado: (2012)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study
por: Deshpande, Sarita S, et al.
Publicado: (2017)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens, Annemie, et al.
Publicado: (2016)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial
por: Oddone, Francesco, et al.
Publicado: (2015)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue, Kenji, et al.
Publicado: (2012)

Ocular Delivery of Bimatoprost-Loaded Solid Lipid Nanoparticles for Effective Management of Glaucoma
por: Satyanarayana, Sandeep Divate, et al.
Publicado: (2023)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell, Joanna H, et al.
Publicado: (2014)

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
por: Zaky, Mohamed S., et al.
Publicado: (2023)

Hirsutism following the use of bimatoprost eyedrops for glaucoma
por: Kaliaperumal, Subashini, et al.
Publicado: (2014)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: Craven, E Randy, et al.
Publicado: (2010)

Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Medeiros, Felipe A., et al.
Publicado: (2022)

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]
por: Zeitz, Oliver, et al.
Publicado: (2005)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
por: Brief, Gerrett, et al.
Publicado: (2010)

Bimatoprost-Loaded Ocular Inserts as Sustained Release Drug Delivery Systems for Glaucoma Treatment: In Vitro and In Vivo Evaluation
por: Franca, Juçara Ribeiro, et al.
Publicado: (2014)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat, Lutz E, et al.
Publicado: (2016)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
por: Malvankar-Mehta, Monali S, et al.
Publicado: (2019)

24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
por: Craven, E. Randy, et al.
Publicado: (2019)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz, Esperanza, et al.
Publicado: (2014)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost
por: Law, Simon K
Publicado: (2007)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Clinical effectiveness of currently available low-vision devices in glaucoma patients with moderate-to-severe vision loss
por: Patodia, Yogesh, et al.
Publicado: (2017)

Trends in Glaucoma Filtration Procedures: A Retrospective Administrative Health Records Analysis Over a 13-Year Period in Canada
por: Kansal, Vinay, et al.
Publicado: (2020)

Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study
por: Petricca, Sabrina, et al.
Publicado: (2022)

Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
por: Wang, Kaidi, et al.
Publicado: (2014)

Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study
por: Menon, Meena G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upqegq1ifl9c9tsuqjuuniu7kv